The FDA has approved GSK’s Exdensur (depemokimab-ulaa) as an add-on maintenance treatment for severe asthma with an eosinophilic phenotype in patients ages 12 and older.
The approval is based on data from the drugmaker’s SWIFT-1 and SWIFT-2 trials, which showed a 58% and 48% reduction in annualized asthma exacerbations, respectively, compared to placebo, according to a Dec. 16 news release from GSK. A pooled analysis also found a 72% reduction in exacerbations requiring hospitalization or emergency department visits.
Depemokimab, a twice-yearly treatment, has an extended half-life for “sustained suppression of disease-driving type 2 inflammation,” potentially reducing burden on health systems, according to the release.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
